TTRX
Turn Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$10.74
+1.61%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 56.8K | — | — | — | 52.7K |
| Gross Profit | (56.8K) | — | — | — | (52.7K) |
| Operating Expenses | |||||
| R&D Expense | 778.1K | 265.6K | 246.0K | 7.5K | — |
| SG&A Expense | 6.1M | 5.6M | 1.6M | 2.3M | 4.2M |
| General & Admin Expense | — | 5.6M | 1.6M | 2.3M | 4.2M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | (52.7K) |
| Total Operating Expenses | 6.9M | 5.9M | 1.8M | 2.3M | 4.2M |
| Cost and Expenses | 7.0M | 5.9M | 1.8M | 2.3M | 4.2M |
| Operating Income (EBIT) | (7.0M) | (5.9M) | (1.8M) | (2.3M) | (4.2M) |
| Non-Operating | |||||
| Interest Income | 69.0K | 29.6K | 28.7K | 15.9K | — |
| Interest Expense | 241.4K | — | — | — | 85.4K |
| Net Interest Income | (172.4K) | 29.6K | 28.7K | 15.9K | (85.4K) |
| Other Non-Op Income/Expense | (1.5M) | 2.7M | 28.7K | 15.9K | (76.3K) |
| Non-Operating Income (excl Interest) | (2.8M) | (2.7M) | (28.7K) | (15.9K) | — |
| EBT (Pre-Tax Income) | (8.4M) | (3.2M) | (1.8M) | (2.3M) | (4.3M) |
| Income Tax Expense | — | — | — | — | 800.00 |
| Bottom Line | |||||
| Net Income | (8.4M) | (3.2M) | (1.8M) | (2.3M) | (4.3M) |
| Earnings from Cont. Ops | (8.4M) | (3.2M) | (1.8M) | (2.3M) | (4.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (8.4M) | (3.2M) | (1.8M) | (2.3M) | (4.3M) |
| Per Share | |||||
| Basic EPS | ($0.29) | ($0.23) | ($0.13) | ($0.17) | ($0.33) |
| Diluted EPS | ($0.29) | ($0.23) | ($0.13) | ($0.17) | ($0.33) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 29.8M | 13.7M | 13.4M | 13.2M | 13.2M |
| Diluted Shares Outstanding | 29.8M | 13.7M | 13.4M | 13.2M | 13.2M |
| Profitability Metrics | |||||
| EBITDA | (4.2M) | (3.1M) | (1.7M) | (2.2M) | (4.2M) |
| D&A | 56.8K | 52.7K | 47.5K | 43.9K | 52.7K |
| EBIT | (4.2M) | (3.2M) | (1.8M) | (2.3M) | (4.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026